Xeris Biopharma Holdings Inc (NASDAQ: XERS) on Monday, soared 4.36% from the previous trading day, before settling in for the closing price of $4.82. Within the past 52 weeks, XERS’s price has moved between $1.69 and $4.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 197.66% over the last five years. The company achieved an average annual earnings per share of 83.57%. With a float of $142.00 million, this company’s outstanding shares have now reached $149.43 million.
The firm has a total of 394 workers. Let’s measure their productivity. In terms of profitability, gross margin is 79.19%, operating margin of -16.57%, and the pretax margin is -28.12%.
Xeris Biopharma Holdings Inc (XERS) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Xeris Biopharma Holdings Inc is 7.76%, while institutional ownership is 43.38%. The most recent insider transaction that took place on Aug 12 ’24, was worth 10,147. In this transaction Director of this company bought 4,515 shares at a rate of $2.25, taking the stock ownership to the 25,200 shares. Before that another transaction happened on Aug 09 ’24, when Company’s Director bought 4,285 for $2.37, making the entire transaction worth $10,134. This insider now owns 20,685 shares in total.
Xeris Biopharma Holdings Inc (XERS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 83.57% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Xeris Biopharma Holdings Inc (XERS) is currently performing well based on its current performance indicators. A quick ratio of 1.19 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.81.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach 0.12 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Analysing the last 5-days average volume posted by the [Xeris Biopharma Holdings Inc, XERS], we can find that recorded value of 4.14 million was better than the volume posted last year of 2.24 million. As of the previous 9 days, the stock’s Stochastic %D was 93.36%. Additionally, its Average True Range was 0.27.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 98.22%, which indicates a significant increase from 97.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.72% in the past 14 days, which was higher than the 47.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.72, while its 200-day Moving Average is $3.03. Now, the first resistance to watch is $5.15. This is followed by the second major resistance level at $5.27. The third major resistance level sits at $5.47. If the price goes on to break the first support level at $4.83, it is likely to go to the next support level at $4.63. Should the price break the second support level, the third support level stands at $4.51.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
Market capitalization of the company is 774.32 million based on 153,940K outstanding shares. Right now, sales total 203,070 K and income totals -54,840 K. The company made 60,100 K in profit during its latest quarter, and -5,110 K in sales during its previous quarter.
